InvestorsHub Logo
Followers 30
Posts 4277
Boards Moderated 0
Alias Born 03/20/2011

Re: dcaf7 post# 58

Sunday, 07/16/2023 2:13:06 PM

Sunday, July 16, 2023 2:13:06 PM

Post# of 106
Point taken.

I think what i was trying to get at was whether BDTX-1535 will demonstrate any effectiveness against
exon 20 insertion or T790M mutations.

If i'm reading the clinical site and BDTX presentation correctly exon 20 and T790M are omitted from the NSCLC trial, however are not omitted from the GBM part.

Osimertinib appears to be ineffective on both mutations which are known to be resistant to TKIs.

https://pubmed.ncbi.nlm.nih.gov/36994936/

Other refs:

https://classic.clinicaltrials.gov/ct2/show/NCT05256290

https://investors.blackdiamondtherapeutics.com/static-files/e5782d24-154c-4d23-af99-a5c3b3b3f9e1
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BDTX News